Ascentage Pharma Group International (NASDAQ:AAPG) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.
Founded in 2008 by biotechnology entrepreneur Dr. Jackson Hu, Ascentage has built integrated discovery and translational research platforms based in Shanghai and Beijing. The company maintains a presence in North America with clinical and regulatory operations in the United States, and collaborates with research institutions and trial sites across Asia-Pacific, Europe and North America to advance its programs swiftly through Phase I and Phase II studies.
Ascentage’s clinical development portfolio spans indications such as acute myeloid leukemia, non-Hodgkin’s lymphoma, lung cancer and colorectal cancer, with biomarker‐driven strategies to optimize patient selection and response assessment. In addition to its oncology focus, the company is exploring novel applications in viral diseases by targeting host–virus interactions through modulation of apoptotic pathways.
In November 2020, Ascentage Pharma Group International completed its initial public offering on the NASDAQ Global Market under the ticker symbol “AAPG.” Led by Dr. Jackson Hu and a management team with deep expertise in oncology drug development, clinical operations and regulatory affairs, Ascentage aims to advance its pipeline toward regulatory submissions and commercialization to address significant unmet medical needs globally.
